Recently, we have found that monitoring connexin (Cx) proteins Cx26 and Cx46 in neoadjuvant treated breast cancer allowed refinement of intermediate prognostic subgroups of residual tumor classifications [7]. The gene discussed is GJB2; the disease is neoplasm.